Refine
Has Fulltext
- yes (21)
Is part of the Bibliography
- yes (21)
Year of publication
- 2015 (21) (remove)
Document Type
- Journal article (14)
- Doctoral Thesis (7)
Keywords
- endothelial cells (4)
- expression (3)
- blood-brain barrier (2)
- in vitro (2)
- mice (2)
- rat (2)
- rolipram (2)
- sepsis (2)
- tight junctions (2)
- 4D (1)
- ARDS (1)
- Anwenderschulung (1)
- Assistierte Beatmung (1)
- BV-2 (1)
- Blut-Nerven-Schranke (1)
- CNS injury (1)
- Chronische Schmerzen (1)
- Chronischer Schmerz (1)
- Claudin (1)
- Entzündung (1)
- Ernährungstherapie (1)
- GBM (1)
- GRO alpha (1)
- HES (1)
- HK-2 Zellen (1)
- Hydroxyäthylstärke (1)
- HÄS (1)
- IMA2.1 (1)
- Inflammation (1)
- Intensivstation (1)
- Interdisziplinäre Schmerztherapie (1)
- Karbonylierung (1)
- Kohlenstoffmonoxid (1)
- Kolloidale Volumenersatztherapie (1)
- Lungprotective Ventilation (1)
- Mangansuperoxiddismutase (1)
- Nephrotoxizität (1)
- Neurotoxizität (1)
- OSC (1)
- PDE4-inhibitor roflumilast (1)
- Postaggressorisches Syndrom (1)
- Postagressionsstoffwechsel (1)
- Schmerztagesklinik (1)
- Simulation (1)
- Starch volumetherapy nephrotoxicity HK-2 cells (1)
- Transwell® system (1)
- User Training (1)
- VACV (1)
- Volumensubstitution (1)
- Volumentherapie (1)
- acute liver failure (1)
- acute lung injury (1)
- aggregation (1)
- anesthesiologists (1)
- angiogenesis (1)
- astrocytes (1)
- automated external defibrillators (1)
- barrier (1)
- barrier properties (1)
- blood (1)
- blood brain barrier (1)
- cEND (1)
- calcium level (1)
- cardio-pulmonary resuscitation (1)
- cell stretch (1)
- central nervous system (1)
- cerebral ischemia (1)
- chest-compression rate (1)
- children (1)
- colloids (1)
- corticosteroids (1)
- creatinine (1)
- cyclodextrin formulations (1)
- cytokine expression (1)
- cytotoxicity (1)
- differentially expressed genes (1)
- disease (1)
- encephalitis dementia (1)
- endotoxemia (1)
- ether (1)
- etomidate (1)
- exposure (1)
- fetal lung (1)
- fluorescein isothiocyanate (1)
- fluorescence microscopy (1)
- formulations (1)
- gene ontology (1)
- glucocorticoids (1)
- histopathology (1)
- human immunodeficiency virus (1)
- hydrochloride (1)
- in-hospital cardiac arrest (1)
- infiltration (1)
- inflammation (1)
- inflammatory pain (1)
- inhibition (1)
- intestinal absorption (1)
- involvement (1)
- kidneys (1)
- kritisch-kranke Patienten (1)
- lungenprotektive Beatmung (1)
- mechanisms (1)
- microarray (1)
- microglia (1)
- molecular docking (1)
- molecular dynamics (1)
- molecular liphophilicity potential (1)
- mouse models (1)
- multiwalled carbon nanotube (1)
- necrosis factor alpha (1)
- nervous system (1)
- nitric oxide (1)
- oxygen-glucose deprivation (1)
- performance (1)
- peripheral nerve injury (1)
- pharmaceutical applications (1)
- phosphodiesterase (1)
- polarization (1)
- pregnancy (1)
- preterm birth (1)
- primary microvascular endothelial cells (1)
- propranolol (1)
- protein expression (1)
- protein-protein interaction network (1)
- receptor antagonist (1)
- receptors (1)
- respiratory distress syndrome (1)
- safety (1)
- sciatic nerve (1)
- sensory neurons (1)
- sevoflurane (1)
- sheep (1)
- team-training (1)
- traumatic brain injury (1)
- tumor (1)
- tumor microenvironment (1)
- ulfobutylether-\(\beta\)-cyclodextrin (1)
- urine (1)
- water (1)
Institute
- Klinik und Poliklinik für Anästhesiologie (ab 2004) (21) (remove)
Sonstige beteiligte Institutionen
EU-Project number / Contract (GA) number
- 241778 (2)
- 602133 (1)
- HEALTH-F2-2009-241778 (1)
Die Blut-Nerven-Schranke stellt eine Barriere zwischen den Axonen und dem Gewebe, das sie umgibt, dar. Durch verschiedene Mechanismen wird die intraneurale Homöostase aufrecht erhalten, welche für die Funktion der Axone essentiell ist. Auf der einen Seite stellt die Blut-Nerven-Schranke einen Schutzmechanismus für Nerven dar. Auf der anderen Seite erschwert sie die Applikationen von Pharmaka, z.B. Analgetika, sodass bis dato Lokalanästhetika die einzige Substanzklasse darstellen, welche zur gezielten örtlichen, analgetischen Therapie in der breiten Verwendung ist. Das Netzwerk der Tight junctions im Perineurium ist eine Schlüsselkomponente für die Funktion der Blut-Nerven-Schranke. Es konnte experimentell gezeigt werden, dass durch pharmakologische Interaktion mit den Tight Junctions eine Schrankenöffnung erzielt werden kann. Dieser Effekt wurde durch unsere Arbeitsgruppe nachgewiesen für das von der N-terminalen Schleife des Claudin-1 abgeleitete Peptid C1C2, hypertone Substanzen, wie HTS und den Gewebeplasminogenaktivator tPA. Durch Anwendung solcher Wirkstoffvermittler könnte das Axon für andere Substanzklassen erreichbar werden. Die Fragestellung dieser Arbeit war, ob sich durch die lokale Anwendung dieser Pharmaka am N. ischiadicus von Wistar Ratten toxische Effekte ergeben. Hierzu wurden immunhistochemische Färbungen mit einem Anti-CD68- Antikörper zur Darstellung von endoneuralen Makrophagen als Zeichen einer lokalen Entzündungsreaktion verwendet. Weiterhin wurden die Nerven mit Hilfe histomorphometrischer Analysen auf morphologische Veränderungen hin untersucht. Keine der untersuchten Substanzen bewirkte eine Zunahme von endoneuralen Makrophagen im Vergleich zur scheinbehandelten Kontrollgruppe. Die Positivkontrolle eines N. ischiadicus nach chronischer Konstriktionsläsion (CCI) zeigte hingegen eine massive Vermehrung endoneuraler Makrophagen. Bei der morphometrischen Analyse zeigte sich nur bei der mit tPA behandelten Gruppe eine Abnahme der g-Ratio, welche das Verhältnis von Myelinschicht zu Faserdurchmesser wiederspiegelt. Die anderen Teilaspekte der Untersuchung blieben unauffällig. Aus dieser Arbeit kann geschlossen werden, dass sich mit den verwendeten Untersuchungsmethoden für keine der untersuchten Substanzen eine lokal toxische Wirkung nachweisen lässt. Um die Aussagekraft bezüglich der Anwendungssicherheit weiter zu erhöhen, wären im weiteren Verlauf Versuchsreihen mit Blick auf mögliche Langzeitwirkungen und etwaige systemtoxische Wirkungen von besonderer Bedeutung
The Unrecognized Effects of Phosphodiesterase 4 on Epithelial Cells in Pulmonary Inflammation
(2015)
Acute pulmonary inflammation is characterized by migration of polymorphonuclear neutrophils (PMNs) into the different compartments of the lung, passing an endothelial and epithelial barrier. Recent studies showed evidence that phosphodiesterase (PDE) 4-inhibitors stabilized endothelial cells. PDE4B and PDE4D subtypes play a pivotal role in inflammation, whereas blocking PDE4D is suspected to cause gastrointestinal side effects. We thought to investigate the particular role of the PDE4-inhibitors roflumilast and rolipram on lung epithelium. Acute pulmonary inflammation was induced by inhalation of LPS. PDE4-inhibitors were administered i.p. or nebulized after inflammation. The impact of PDE4-inhibitors on PMN migration was evaluated in vivo and in vitro. Microvascular permeability, cytokine levels, and PDE4B and PDE4D expression were analyzed. In vivo, both PDE4-inhibitors decreased transendothelial and transepithelial migration even when administered after inflammation, whereas roflumilast showed a superior effect compared to rolipram on the epithelium. Both inhibitors decreased TNF\(\alpha\), IL6, and CXCL2/3. CXCL1, the strong PMN chemoattractant secreted by the epithelium, was significantly more reduced by roflumilast. In vitro assays with human epithelium also emphasized the pivotal role of roflumilast on the epithelium. Additionally, LPS-induced stress fibers, an essential requirement for a direct migration of PMNs into the alveolar space, were predominantly reduced by roflumilast. Expression of PDE4B and PDE4D were both increased in the lungs by LPS, PDE4-inhibitors decreased mainly PDE4B. The topical administration of PDE4-inhibitors was also effective in curbing down PMN migration, further highlighting the clinical potential of these compounds. In pulmonary epithelial cells, both subtypes were found coexistent around the nucleus and the cytoplasm. In these epithelial cells, LPS increased PDE4B and, to a lesser extend, PDE4D, whereas the effect of the inhibitors was prominent on the PDE4B subtype. In conclusion, we determined the pivotal role of the PDE4-inhibitor roflumilast on lung epithelium and emphasized its main effect on PDE4B in hyperinflammation.
The blood-brain barrier (BBB), made up of endothelial cells of capillaries in the brain, maintains the microenvironment of the central nervous system. During ischemia and traumatic brain injury (TBI), cellular disruption leading to mechanical insult results to the BBB being compromised. Oxygen glucose deprivation (OGD) is the most commonly used in vitro model for ischemia. On the other hand, stretch injury is currently being used to model TBI in vitro. In this paper, the two methods are used alone or in combination, to assess their effects on cerebrovascular endothelial cells cEND in the presence or absence of astrocytic factors. Applying severe stretch and/or OGD to cEND cells in our experiments resulted to cell swelling and distortion. Damage to the cells induced release of lactate dehydrogenase enzyme (LDH) and nitric oxide (NO) into the cell culture medium. In addition, mRNA expression of inflammatory markers interleukin (I L)-6, IL-1\(\alpha\) chemokine (C-C motif) ligand 2 (CCL2) and tumor necrosis factor (TNF)-\(\alpha\) also increased. These events could lead to the opening of calcium ion channels resulting to excitotoxicity. This could be demonstrated by increased calcium level in OGD-subjected cEND cells incubated with astrocyte-conditioned medium. Furthermore, reduction of cell membrane integrity decreased tight junction proteins claudin-5 and occludin expression. In addition, permeability of the endothelial cell monolayer increased. Also, since cell damage requires an increased uptake of glucose, expression of glucose transporter glut1 was found to increase at the mRNA level after OGD. Overall, the effects of OGD on cEND cells appear to be more prominent than that of stretch with regards to TJ proteins, NO, glutl expression, and calcium level. Astrocytes potentiate these effects on calcium level in cEND cells. Combining both methods to model TBI in vitro shows a promising improvement to currently available models.
Following the early experiences in aviation, medical simulation has rapidly
evolved into one of the most novel educational tools of the last three decades. In addition to its
use in training individuals or teams in crisis resource management, simulation has been studied as
a tool to evaluate technical and non-technical skills of individuals as well as, more recently,
entire medical teams.
It is usually fairly difficult to obtain clinical reference data from critical events to refute
claims that the management of actual events fell below what could reasonably be expected and we
demonstrated the use of rank order statistics to calculate quantiles with confidence limits for
management times of critical obstetrical events using data from realistic simulation. This approach
could be used to describe the distribution of treatment times in order to assist in deciding what
performance may constitute an outlier. It can also identify particular challenges of clinical
practice and allow the development of educational curricula. While the information derived from
simulation has to be interpreted with a high degree of caution for a clinical context, it may
represent a further ‘added value’ or important step in establishing simulation as a training tool
and to provide information that could be used in an appropriate clinical context for adverse
events. Large amounts of data (such as from a simulation registry) would allow the calculation of
acceptable confidence intervals for the required
outcome parameters as well as actual tolerance limits.
Background
There are not enough clinical data from rare critical events to calculate statistics to decide if the management of actual events might be below what could reasonably be expected (i.e. was an outlier).
Objectives
In this project we used simulation to describe the distribution of management times as an approach to decide if the management of a simulated obstetrical crisis scenario could be considered an outlier.
Design
Twelve obstetrical teams managed 4 scenarios that were previously developed. Relevant outcome variables were defined by expert consensus. The distribution of the response times from the teams who performed the respective intervention was graphically displayed and median and quartiles calculated using rank order statistics.
Results
Only 7 of the 12 teams performed chest compressions during the arrest following the 'cannot intubate/cannot ventilate' scenario. All other outcome measures were performed by at least 11 of the 12 teams. Calculation of medians and quartiles with 95% CI was possible for all outcomes. Confidence intervals, given the small sample size, were large.
Conclusion
We demonstrated the use of simulation to calculate quantiles for management times of critical event. This approach could assist in deciding if a given performance could be considered normal and also point to aspects of care that seem to pose particular challenges as evidenced by a large number of teams not performing the expected maneuver. However sufficiently large sample sizes (i.e. from a national data base) will be required to calculate acceptable confidence intervals and to establish actual tolerance limits.
The objective of the present investigation was to study the ability of sulfobutylether-\(\beta\)-cyclodextrin (SBECD) to form an inclusion complex with sevoflurane (SEV), a volatile anesthetic with poor water solubility. The inclusion complex was prepared, characterized and its cellular toxicity and blood-brain barrier (BBB) permeation potential of the formulated SEV have also been examined for the purpose of controlled drug delivery. The SEV-SBE\(\beta\)CD complex was nontoxic to the primary brain microvascular endothelial (pEND) cells at a clinically relevant concentration of sevoflurane. The inclusion complex exhibited significantly higher BBB permeation profiles as compared with the reference substance (propranolol) concerning calculated apparent permeability values (P\(_{app}\)). In addition, SEV binding affinity to SBE\(\beta\)CD was confirmed by a minimal Gibbs free energy of binding (ΔG\(_{bind}\)) value of -1.727 ± 0.042 kcal・mol\(^{-1}\) and an average binding constant (K\(_{b}\)) of 53.66 ± 9.24 mM indicating rapid drug liberation from the cyclodextrin amphiphilic cavity.
Chronische Schmerzen sind ein weit verbreitetes, anspruchsvoll zu behandelndes Krankheitsbild. Hier setzten interdisziplinäre Therapieverfahren an, deren Effektivität in zahlreichen Studien nachgewiesen werden konnte. Die Behandlung in der Schmerzta-gesklinik der Universitätsklinik Würzburg erfolgt nach einem multimodalen Behand-lungskonzept, das auf dem bio-psycho-sozialen Modell der Schmerzentstehung basiert. Dieses beschreibt die Schmerzverarbeitung als komplexes Geschehen, das auf mehreren Ebenen stattfindet. Mit diesem Wissen über die Mehrdimensionalität chronischer Schmerzen soll auch diese Arbeit die Qualität der Behandlung in der Schmerztageskli-nik auf unterschiedlichen Ebenen untersuchen. Berücksichtigt werden die physische Komponente, psychische Komponente, Komponente Lebensqualität und Zufriedenheit mit der Behandlung. Zudem wird der Einfluss der Therapie auf die Arbeitsfähigkeit der Patienten betrachtet und es wird überprüft, ob sich Prädiktoren für den Behandlungser-folg formulieren lassen. Zur Erfolgskontrolle dienten zahlreiche Elemente aus dem Fra-gebogen „Evaluation des Therapieerfolgs“. Die Messzeitpunkte lagen jeweils zu Beginn der Behandlung (t1) und am Ende der Behandlung (t3).
In der vorliegenden retrospektiven Auswertung wurden die Daten von 619 Patienten analysiert, die im Zeitraum Januar 2007 bis Dezember 2011 in der Schmerztagesklinik Würzburg behandelt wurden (68,9% Frauen, mittleres Alter 54,8 Jahre, 73,1% Chroni-fizierungsgrad III). Insgesamt konnte gezeigt werden, dass sich in allen vier Komponen-ten (körperliche Verfassung, Psyche, Lebensqualität und Zufriedenheit mit der Behand-lung) signifikante Verbesserungen für die Patienten ergaben.
Hinsichtlich der Arbeitsfähigkeit konnten keine signifikanten Verbesserungen durch die Behandlung erreicht werden. Mittels Regressionsanalysen konnten verschiedene Vari-ablen aus den Bereichen Soziodemographie und Chronifizierungsgrad als mögliche Prädiktoren für den Behandlungserfolg gefunden werden.
Objective: To investigate the impact of the phophodiesterase-4 inhibition (PD-4-I) with rolipram on hepatic integrity in lipopolysaccharide (LPS) induced hyperinflammation. Materials and Methods: Liver microcirculation in rats was obtained using intravital microscopy. Macrohemodynamic parameters, blood assays, and organs were harvested to determine organ function and injury. Hyperinflammation was induced by LPS and PD-4-I rolipram was administered intravenously one hour after LPS application. Cell viability of HepG2 cells was measured by EZ4U-kit based on the dye XTT. Experiments were carried out assessing the influence of different concentrations of tumor necrosis factor alpha (TNF-α) and LPS with or without PD-4-I. Results: Untreated LPS-induced rats showed significantly decreased liver microcirculation and increased hepatic cell death, whereas LPS + PD-4-I treatment could improve hepatic volumetric flow and cell death to control level whithout influencing the inflammatory impact. In HepG2 cells TNF-α and LPS significantly reduced cell viability. Coincubation with PD-4-I increased HepG2 viability to control levels. The heme oxygenase 1 (HO-1) pathway did not induce the protective effect of PD-4-I. Conclusion: Intravenous PD-4-I treatment was effective in improving hepatic microcirculation and hepatic integrity, while it had a direct protective effect on HepG2 viability during inflammation.
We report on a nine-month-old girl who presented with persisting cough, and diminished ventilation of the left hemithorax. Viral pneumonia was suspected after Adenovirus detection by PCR, but chest X-rays showed a persistent shadowing of the left hemithorax and persistent coughing despite clinical improvement. Because of the discrepancy between clinical and radiological signs further investigations by ultrasound and CT scan were performed, which visualized an intrathroracic tumor. Histopathology confirmed diagnosis of a teratoma.
This case highlights the need for careful evaluation by the treating physicians. If the chest X-ray provides a discrepancy to the clinical findings or persistent pathologies exist, differential diagnosis should be discussed and further diagnostics be performed.
Multiple Antenatal Dexamethasone Treatment Alters Brain Vessel Differentiation in Newborn Mouse Pups
(2015)
Antenatal steroid treatment decreases morbidity and mortality in premature infants through the maturation of lung tissue, which enables sufficient breathing performance. However, clinical and animal studies have shown that repeated doses of glucocorticoids such as dexamethasone and betamethasone lead to long-term adverse effects on brain development. Therefore, we established a mouse model for antenatal dexamethasone treatment to investigate the effects of dexamethasone on brain vessel differentiation towards the blood-brain barrier (BBB) phenotype, focusing on molecular marker analysis. The major findings were that in total brains on postnatal day (PN) 4 triple antenatal dexamethasone treatment significantly downregulated the tight junction protein claudin-5, the endothelial marker Pecam-1/CD31, the glucocorticoid receptor, the NR1 subunit of the N-methyl-D-aspartate receptor, and Abc transporters (Abcb1a, Abcg2 Abcc4). Less pronounced effects were found after single antenatal dexamethasone treatment and in PN10 samples. Comparisons of total brain samples with isolated brain endothelial cells together with the stainings for Pecam-1/CD31 and claudin-5 led to the assumption that the morphology of brain vessels is affected by antenatal dexamethasone treatment at PN4. On the mRNA level markers for angiogenesis, the sonic hedgehog and the Wnt pathway were downregulated in PN4 samples, suggesting fundamental changes in brain vascularization and/or differentiation. In conclusion, we provided a first comprehensive molecular basis for the adverse effects of multiple antenatal dexamethasone treatment on brain vessel differentiation.